Previously, Joaquin served as the Vice Chairman of the . Ms. Taubert owns over 76,923 units of Johnson & Johnson stock worth over $35,709,285 and over the last 4 years she sold JNJ stock worth over $0. Duato will receive the award during the Esade Alumni Annual Conference, which will take place on 27th June at Teatre Nacional de Catalunya.. Duato, who was appointed CEO in January 2022, has been selected as the winner of this year's Esade Award for his responsible . About Alex GorskyAlex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson, one of just seven leaders who have served in the dual role since the company was listed on the New York Stock Exchange in 1944. Offers may be subject to change without notice. Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Pronunciation of Joaquin Duato with 4 audio pronunciations. Duato is trilingual, speaking English, Spanish, and Italian. Dow Inc and private company X-energy said on Wednesday they have agreed to develop and demonstrate the first grid-scale next-generation nuclear reactor for an industrial site in North America. [3], Duato began his career in Johnson & Johnson in 1989 when he joined Janssen Pharmaceutica in Spain. Gorsky, who has served as CEO and chairman since 2012, will become. Joaquin has long believed in the power of technology to accelerate progress in healthcare. He is on the Board of Directors at Johnson & Johnson, U.S.-Spain Council, Inc. and Save The Children Federation, Inc . He leads a global workforce in developing and delivering transformational and innovative healthcare solutions in Pharmaceuticals, MedTech, and Consumer Health. Create your free account or log in to continue reading this premium content. Joaquin Duato is the Chief Executive Officer of Johnson & Johnson and serves on its Board of Directors. [1] He is the chief executive officer (CEO) of Johnson & Johnson, an American multinational conglomerate. El gigante de productos de gran consumo y farmacutico Johnson & Johnson tendr un consejero delegado espaol. It was solely about personal and professional growth, not about getting the next job. He leads a global workforce of 135,000 employees in developing and delivering . As CEO of the world's largest healthcare company, Joaquin leads a global workforce of 135,000 employees in developing and delivering transformational and innovative healthcare solutions in Pharmaceuticals, MedTech, and Consumer Health. Highlights from a week-long virtual event bringing Bloomberg Businessweek magazine to life. Duato will also be appointed to the board following his transition to. At Johnson & Johnson, were mobilizing to support organizations that meet underrepresented communities where they are and engage at the grassroots level by involving respected elected representatives, trusted local and national faith leaders, community advocates, and other national and local organizations. A dual citizen of Spain and the U.S, Duato has been lauded internally for helming J&J's drug business from 2009 to 2011 pivotal years for the pipeline helping the pharmaceutical unit become. Joaquin Duato of Johnson & Johnson explains why frontline health workers are critical in delivering health for all and why children's health is a top prior. Cautions Concerning Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Your use of the information on this site is subject to the terms of our Legal Notice. "Mr. Duato's international . Johnson & Johnson announced Thursday evening that Joaquin Duato will become CEO effective Jan. 3, replacing Alex Gorsky. In March, the two executives clinched a deal in which Merck would manufacture J&Js Covid-19 vaccine. Mr. Duato, age 59, is currently Vice Chairman of the Company's Executive Committee and provides strategic direction for the Pharmaceutical and Consumer Health sectors and oversees the Global Supply Chain, Technology and Health & Wellness teams. As part of this, were also partnering with leading organizations on vaccine education, including the National Hispanic Medical Associations #Vaccinate4All effort. We walk the walk.. It's a role that builds on his 33-year career at the company, working across all business sectors and in multiple countries around the globe. Joaquin Duato is Chairman of the Board and Chief Executive Officer of Johnson & Johnson, the world's largest, most diversified healthcare products company. A longtime advocate of diversity and inclusion and supporter of veterans issues, Alex currently sits on the Board of Directors of Apple, IBM, JPMorgan Chase, NewYork-Presbyterian Hospital, and the Travis Manion Foundation, and serves on the Wharton School of the University of Pennsylvania Board of Advisors. All Rights Reserved. Duato will succeed Alex Gorsky, who will step down from his role as executive chairman following a brief transitional period. Continue reading your article with. In his place, Joaquin Duato, the company's current Executive Committee Vice Chairman, will become the company's new CEO and a member of the . 5 To put better health in reach for everyone and drive vaccine uptake, we need to meet people where they are. LL: What was the basis for J&J to pursue emergency use authorization? JD: The virus does not recognize borders. And what we do best is to continue to develop medicines, medical devices, consumer products that improve consumer lives and also are able to address patients' needs.". Alex Gorsky, currently chairman and CEO, will serve as executive chairman of Johnson & Johnson and transition the CEO role to Joaquin Duato, currently vice chairman of the company's executive committee, effective January 3, 2022. Already a speaker of English, Spanish and Italian, he used that brief stint to learn a different language. 3 /5. A believer in the power of technology to accelerate progress in healthcare, Joaquin is leading Johnson & Johnson to harness data science and intelligent automation to solve the worlds toughest health challenges. Got a confidential news tip? LL: Tell me about something J&J is doing to address vaccination hesitancy among the LatinX community that youre particularly proud of? LL: What is Johnson & Johnson doing to combat COVID-19 beyond vaccine development? They averaged a 15% annual return, in line with the S&P 500 Index. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. His career in healthcare was influenced by his family. Joaquin Duato, J&J CEO (Photo by Charles Sykes/Invision/AP) January 25, 2022 12:50 PM EST. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned Cautionary Note Regarding Forward-Looking Statements and Item 1A. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Gorsky also started his J&J career over three decades ago as a sales representative with Janssen Pharmaceuticals in 1988, and had been at the helm of the company for nearly a decade. This site is governed solely by applicable U.S. laws and governmental regulations. [5] Duato was past chair of Pharmaceutical Research and Manufacturers of America (PhRMA). Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. All Rights Reserved. Johnson & Johnsons new CEO Duato said he is honored to be the next CEO of the company. Early life and education [ edit] Duato grew up in Valencia, Spain. REGISTER BELOW, Why Johnson & Johnson is splitting itself into two publicly traded companies, How AI is detecting heart attack risk and aiming to outsmart Americas No. Pharma relies on people who come from a scientific background, but historically within STEM [science, technology, engineering, and mathematics], youve seen more men, he says. We have lots of information about Joaquin: religious views are listed as Christian, ethnicity is Caucasian, and political affiliation is none. Duato, the current vice chairman of the executive committee, will take the reins and a seat on the board from Jan. 3. Duato, 59, is a three-decade veteran of J&J, as is Gorsky. While Duato doesnt share specific experiences or anecdotes, he notes that being mentored was hugely important to his development as both a professional and a person and that every one of his mentors along the way happened to be women. Partnering with minority health and community advocacy groups, such as the National Black Church Initiative (NBCI), 3. Gorsky, the . I believe that moving forward, we will take the lessons we have learned from the COVID-19 pandemic humanitarian crisis as we look to consider and prioritize the health of all communities, patients, consumers, and their families. Machine learning, when combined with genetics, is also accelerating the discovery and development of new medicines. New J&J CEO Joaquin Duato promises an aggressive M&A hunt in quest to grow pharma sales. That was a better performance than rival drugmakers Pfizer Inc. and Merck & Co., though health-care investors who opted for high-flying biotech stocks did better the Nasdaq Biotechnology Index quadrupled in that span. According to a recent Kaiser Family Foundation study, 75% of Hispanic adults trust their healthcare provider to give them reliable information about the available vaccines. JD: We are a proud supporter of the National Hispanic Medical Association (NHMA) Vaccinate 4 All program that will train and support a cadre of physician leaders around the country to speak with local, regional and national media. Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board. Contact Us with any questions or search this site for more information. Join us at MM+M Transform: The New Era of Connectivity for an in-depth look at trends likely to inform the industrys evolution over the next 18 months. On the edge of Johnson & Johnsons New Brunswick, New Jersey campus, Duato is giving his first sit-down interview from within the companys oldest building, which once produced energy for its factories. Joaquin Duato is the Chief Executive Officer of Johnson & Johnson and serves on its Board of Directors. Were only able to tackle this problem at home if we address it worldwide. Pharma. The pharma unit Duato leads generated $33.5 billion in sales last year, growing 7.5% (compared with 4% growth for Johnson & Johnson overall). 4. In addition, she makes $7,097,300 as Executive Vice President - Worldwide Chairman and . Joaquin Duato Chairman of the Board and Chief Executive Officer New Brunswick, New Jersey, United States 38K followers 500+ connections Join to follow Johnson & Johnson Esade About I believe that. The former army captain and endurance athlete who takes spin classes alongside his employees has long been speculated to one day seek political office. "All of them are providing significant improvements in the standard of care, and at the same time, all of them with more than a billion-dollar potential," he said. we must have a workforce that generally reflects that ethnic and . (RTTNews) - Johnson & Johnson said that its vice chairman, Joaquin Duato, will become chief executive officer of the company on 3rd January 2022, with Chairman and chief . During his tenure, J&J's market capitalization rose to over $460 billion from nearly $180 billion. J&J announced in November that it is planning to split into two publicly traded companies: one focusing on consumer health, and the other housing its prescription-drug and medical-device. Johnson & Johnson JNJ has long been viewed as a bellwether stock for other health care companies, given its early slot in the earnings calendar and a business model that spans everything from hip implants to rheumatoid arthritis drugs and Band-Aids. Over our more than 25 years of working together, he has always demonstrated a passion for solving complex medical and business challenges. Duato is a dual citizen of Spain and the United States. Our Company has an unmatched healthcare platform: we are a global pharmaceutical leader with a robust pipeline of transformational and innovative medicines, our Medical Device business is at the forefront of applying cutting-edge technology to deliver physician and patient-centric products and solutions and our Consumer Health business continues to evolve its portfolio of iconic heritage brands and innovative growth brands, he said.
You are now reading joaquin duato ethnicity by
Art/Law Network
